Drug Information

Drug General Information
Drug ID
D00BUO
Former ID
DIB011788
Drug Name
MM-141
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 2 [525130]
Target and Pathway
Target(s) Insulin-like growth factor I receptor Target Info Modulator [532567]
Receptor protein-tyrosine kinase erbB-3 Target Info Modulator [532567]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
HIF-1 signaling pathway
FoxO signaling pathway
Oocyte meiosis
Endocytosis
PI3K-Akt signaling pathway
AMPK signaling pathway
Focal adhesion
Adherens junction
Signaling pathways regulating pluripotency of stem cells
Long-term depression
Ovarian steroidogenesis
Progesterone-mediated oocyte maturation
Pathways in cancer
Transcriptional misregulation in cancer
Proteoglycans in cancer
Glioma
Prostate cancer
Melanomahsa04012:ErbB signaling pathway
Calcium signaling pathway
MicroRNAs in cancer
NetPath Pathway TNFalpha Signaling Pathway
PANTHER Pathway Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
Insulin/IGF pathway-protein kinase B signaling cascadeP00012:Cadherin signaling pathway
EGF receptor signaling pathway
Pathway Interaction Database Plasma membrane estrogen receptor signaling
SHP2 signaling
IGF1 pathway
Posttranslational regulation of adherens junction stability and dissassembly
Integrins in angiogenesis
Stabilization and expansion of the E-cadherin adherens junctionerbb2erbb3pathway:ErbB2/ErbB3 signaling events
ErbB receptor signaling network
a6b1 and a6b4 Integrin signaling
Reactome IRS-related events triggered by IGF1R
SHC-related events triggered by IGF1R
WikiPathways Senescence and Autophagy in Cancer
Insulin Signaling
Endochondral Ossification
Focal Adhesion
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
Apoptosis
Signaling Pathways in Glioblastoma
TSH signaling pathway
MicroRNAs in cardiomyocyte hypertrophyWP673:ErbB Signaling Pathway
Apoptosis-related network due to altered Notch3 in ovarian cancer
miR-targeted genes in muscle cell - TarBase
Heart Development
References
Ref 525130ClinicalTrials.gov (NCT02399137) A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 532567MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.